Nemaura Medical Inc.
nemauramedical.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Feb 12, 2024. Its latest SEC filing is a 8-K from Sep 26, 2024.
10-Q for Q3 FY2024, filed Feb 12, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops non-invasive glucose-monitoring patches and digital health programs for people with diabetes and people tracking metabolic health.
10-K for FY2023, filed Jul 13, 2023We are a medical technology company that has developed sugarBEAT®, a non-invasive, flexible, continuous glucose monitoring system, for…View ↗
In addition to this, Nemaura established that proBEATTM, which is based on the sugarBEAT® platform, can be classified under the Wellness…View ↗
We intend to lead in the discovery, development and commercialization of innovative and targeted diagnostic medical devices, and…View ↗
Who Were Their Customers?
People with diabetes can buy sugarBEAT directly from the UK and Ireland marketing partner or through general-practitioner prescriptions; a joint venture and commercial partners cover other territories.
10-K for FY2023, filed Jul 13, 2023We are a medical technology company that has developed sugarBEAT®, a non-invasive, flexible, continuous glucose monitoring system, for…View ↗
An Exclusive Marketing Rights agreement for the UK and Republic of Ireland was signed on March 31, 2014 with Dallas Burston Pharma, a…View ↗
In addition, a joint venture agreement was entered into with MySugar Watch (Europe) Limited (previously known as Dallas Burston Ethitronix…View ↗
Establish licensing or joint venture agreements with other parties to market sugarBEAT® in other geographies. We are in detailed…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Feb 12, 2024
−$2.2MView ↗
- ▲ +26% (Loss)
- vs −$1.7M in Q3 FY2023
-
Jan 3, 2024
Company accepts Nasdaq delisting and plans move to OTC Markets
Nasdaq said trading would be suspended, and the company did not intend to seek review.
Sources
8-K, filed Jan 3, 2024
As previously disclosed, on January 3, 2024, Nemaura Medical Inc. (the “Company”) issued a press release providing a crucial update…View ↗
Broader consumer-health offering
The older report centered on sugarBEAT glucose monitoring for people with diabetes; the latest report also describes proBEAT as a wellness product and a strategy around digital platforms for consumer well-being.
10-K for FY2020, filed Jun 29, 2020 10-K for FY2023, filed Jul 13, 2023We are a medical technology company developing sugarBEAT®, a non-invasive, affordable and flexible continuous glucose monitoring system for…View ↗
Who Did They Compete With?
Competes with Dexcom and Abbott
10-K for FY2023, filed Jul 13, 2023To the best of our knowledge, there are currently no other competing devices on the market that offer continuous glucose monitoring and…View ↗
Loading...
